R. Dekkers, L. A. W. Vijftigschild, A. M. Vonk, E. Kruisselbrink, K. M

Slides:



Advertisements
Similar presentations
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Advertisements

CFTR stabilizes ENaC at the plasma membrane
Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus  Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,
Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel  Emanuela Pesce, Giulia Gorrieri,
Cystic Fibrosis Patients Benefit from Mini Guts
D-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models  Daniel J. Fox, Morris D. Cooper, Cristian A.
CFTR mutation in an Arab patient: Clinical and functional features of 875+1G→A/875+1G→A genotype  Elide Spinelli, Manuela Seia, Paola Melotti, Eleonora.
Elevated levels of miR-145 correlate with SMAD3 down-regulation in Cystic Fibrosis patients  Francesca Megiorni, Samantha Cialfi, Giuseppe Cimino, Riccardo.
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function  Fredrick Van Goor, Haihui Yu, Bill.
Anti-inflammatory effect of miglustat in bronchial epithelial cells
Effect of VX-770 (Ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells  Laura Vachel, Caroline Norez, Frédéric.
K. L. Nash, M. E. Allison, D. McKeon, D. J. Lomas, C. S. Haworth, D
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
Z. Kopeikin, Z. Yuksek, H.-Y. Yang, S.G. Bompadre 
Helmut Ellemunter, Katharina Schüller, Gratiana Steinkamp 
Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation  Venkateshwar Mutyam,
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Cystic Fibrosis Patients Benefit from Mini Guts
Assessment of CFTR function in homozygous R117H-7T subjects
Cirrhosis and other liver disease in cystic fibrosis
Curcumin and genistein additively potentiate G551D-CFTR
Bronchial epithelial cell lines and primary nasal epithelial cells from cystic fibrosis respond differently to cigarette smoke exposure  Mark Thomas Shaw.
Fiona K. Dunlevy, S. Lorraine Martin, Francine de Courcey, J
Johanna F. Dekkers, Peter Van Mourik, Annelotte M
Expression of the inflammatory regulator A20 correlates with lung function in patients with cystic fibrosis  Catriona Kelly, Mark T. Williams, J. Stuart.
Controlled clinical trials in cystic fibrosis — are we doing better?
George T. Kannarkat, Dean J. Tuma, Pamela L. Tuma 
Entry of Burkholderia organisms into respiratory epithelium: CFTR, microfilament and microtubule dependence  Jane B. Taylor, Lisa A. Hogue, John J. LiPuma,
Volume 13, Issue 6, Pages (December 2013)
Function, pharmacological correction and maturation of new Indian CFTR gene mutations  Himanshu Sharma, Mathilde Jollivet Souchet, Isabelle Callebaut,
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Cystic fibrosis mortality trend in Italy from 1970 to 2011
Evaluation of salt supplementation in CF infants
Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: A pilot study  I. Hammana, L. Coderre, S. Potvin, M. Costa,
The Journal of Cystic Fibrosis: Sunny perspectives
P. aeruginosa drives CXCL8 synthesis via redundant toll-like receptors and NADPH oxidase in CFTR∆F508 airway epithelial cells  Lucie Roussel, Guy Martel,
Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators 
Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis
A.H. Gifford  Journal of Cystic Fibrosis 
Treatment of resistant distal intestinal obstruction syndrome with a modified antegrade continence enema procedure  I.J. Clifton, A.M. Morton, N.S. Ambrose,
Shaoyan Zhang, Neel K. Ranganath, Daniel Skinner, David M
Demographics of glucose metabolism in cystic fibrosis
Physiologic endpoints for clinical studies for cystic fibrosis
Measurement of halide efflux from cultured and primary airway epithelial cells using fluorescence indicators  Felix Munkonge, Eric W.F.W. Alton, Charlotte.
Antibacterial properties of the CFTR potentiator ivacaftor
Transepithelial fluctuation analysis of chloride secretion
Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients  Marie-Claire Ishimo, Linda Belson, Sophie Ziai, Emile Levy, Yves.
Narelle S. Cox, Jennifer Follett, Karen O. McKay 
Stimulation of salivary secretion in vivo by CFTR potentiators in Cftr+/+ and Cftr−/− mice  Sabrina Noël, Pierre-Olivier Strale, Luc Dannhoffer, Martina.
D.Y.F. Mak, J. Sykes, A.L. Stephenson, L.C. Lands 
Volume 18, Issue 2, Pages (February 2011)
Determining presence of lung disease in young children with cystic fibrosis: Lung clearance index, oxygen saturation and cough frequency  E.M. Bakker,
Newsome S.J. , Daniel R.M. , Carr S.B. , Bilton D. , Keogh R.H.  
P. aeruginosa LPS stimulates calcium signaling and chloride secretion via CFTR in human bronchial epithelial cells  J.M. Buyck, V. Verriere, R. Benmahdi,
Atrial natriuretic peptide attenuates Ca2+ oscillations and modulates plasma membrane Ca2+ fluxes in rat hepatocytes  Anne K. Green, Olga Zolle, Alec.
Modification of the salivary secretion assay in F508del mice — The murine equivalent of the human sweat test  Karoline Droebner, Peter Sandner  Journal.
Gautham Marigowda, Fang Liu, David Waltz  Journal of Cystic Fibrosis 
Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case– control study  Maarten Verregghen, Harry G. Heijerman, Monique.
Gut dysbiosis in cystic fibrosis
Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis
CFTR modulators and pregnancy: Our work has only just begun
‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis
Sophie Yammine, Florian Singer, Per Gustafsson, Philipp Latzin 
Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis
CFTR, investigated with the two-electrode voltage-clamp technique: the importance of knowing the series resistance  Georg Nagel  Journal of Cystic Fibrosis 
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
Absence of a gender gap in survival
H. White, A.M. Morton, D.G. Peckham, S.P. Conway 
Presentation transcript:

A bioassay using intestinal organoids to measure CFTR modulators in human plasma  R. Dekkers, L.A.W. Vijftigschild, A.M. Vonk, E. Kruisselbrink, K.M. de Winter-de Groot, H.M. Janssens, C.K. van der Ent, J.M. Beekman  Journal of Cystic Fibrosis  Volume 14, Issue 2, Pages 178-181 (March 2015) DOI: 10.1016/j.jcf.2014.10.007 Copyright © 2014 Terms and Conditions

Fig. 1 Functional activity of CFTR modulators in plasma. (A) Pooled plasma from ten healthy donors, VX-770 and forskolin (0.4μM) were combined to stimulate CFTR-S1251N expressing organoids. Swelling relative to t=0min was measured for 60min, and area under the curve (AUC) data were calculated and normalized to stimulation with 2μM of VX-770 in medium. Data were measured at three independent time points in triplicate and presented as mean (±SEM). (B) Normalized AUC measurements of organoid swelling after stimulation with serial dilutions of pooled plasmas containing VX-770 (0.5, 1.5 and 4μM in 100% plasma) using 0.4μM forskolin. Data were measured at three independent time points in triplicate and presented as mean (±SEM). (C) Representative examples of organoids from (B) at t=0 and t=60min for indicated conditions (scale bar indicates 250μm). (D) Swelling of R117H organoids after stimulation with forskolin (0.05μM) and serial dilution of plasma containing VX-770 (2μM in 100% plasma). Data are presented as mean (±SD). (E) Forskolin-induced (5μM) swelling of F508del organoids after 20h incubation with 10% plasma and VX-809 (0, 0.5, 1 or 2μM). Data were measured in triplicate in four independent experiments and presented as mean (±SEM). Journal of Cystic Fibrosis 2015 14, 178-181DOI: (10.1016/j.jcf.2014.10.007) Copyright © 2014 Terms and Conditions

Fig. 2 Variation in VX-770-dependent organoid swelling between plasma samples. (A) CFTR-S1251N expressing organoids were stimulated with 6% plasma from 9 different donors in the absence or presence of VX-770 (60 nM, representing 1μM in 100% plasma) and forskolin (0.5μM). Individual data points were normalized to the average VX-770 response of the 9 plasma samples. (B) The VX-770-dependent part of organoid swelling was calculated by subtraction of the plasma response from the plasma+VX-770 response per plasma in (A). Data were normalized to the average of all data points. All data were measured at three independent time points in triplicate and presented as mean (±SEM). Journal of Cystic Fibrosis 2015 14, 178-181DOI: (10.1016/j.jcf.2014.10.007) Copyright © 2014 Terms and Conditions